Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
127 USD | -0.35% | -3.53% | -7.91% |
Apr. 11 | John Chevedden Files an Exempt Solicitation Statement with Securities and Exchange Commission | CI |
Apr. 05 | Quest Diagnostics Receives Shareholder Proposal from John Chevedden | CI |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.91% | 14.1B | A- | ||
+14.91% | 82.27B | C+ | ||
+11.06% | 29.43B | C+ | ||
-12.02% | 16.82B | B | ||
-4.99% | 15.89B | A- | ||
+0.17% | 12.05B | A- | ||
-29.65% | 12.01B | - | - | |
+21.84% | 11.19B | B- | ||
-5.85% | 11.09B | A- | ||
+44.20% | 10.91B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DGX Stock
- Ratings Quest Diagnostics Incorporated